Dyspnea Market Report 2026

The dyspnea market size has grown strongly in recent years. It will grow from $6.73 billion in 2025 to $7.22 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to chronic respiratory disease prevalence, hospital emergency admissions, smoking-related disorders, aging population, cardiopulmonary disease burden.

The dyspnea market size is expected to see strong growth in the next few years. It will grow to $9.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to portable oxygen systems demand, remote respiratory monitoring, personalized dyspnea management, homecare expansion, digital symptom tracking. Major trends in the forecast period include increasing use of oxygen therapy devices, rising adoption of home-based respiratory care, growing focus on symptom management therapies, integration of breathing and relaxation techniques, improved diagnostic assessment of respiratory disorders.

The increasing prevalence of respiratory diseases is expected to drive the growth of the dyspnea market in the coming years. Respiratory diseases are conditions affecting the lungs and respiratory system, which impair airflow and reduce oxygen exchange. The prevalence of these diseases is rising due to factors such as air pollution, smoking, environmental toxins, climate change, and increased vulnerability in aging populations. The dyspnea market supports this trend because dyspnea acts as a key indicator of impaired lung function, assisting clinicians in diagnosing respiratory conditions, guiding treatment plans, and monitoring disease progression. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, COPD accounted for 3.6% of the total disease burden and represented 50% of the overall burden of respiratory diseases in 2023. In 2022, COPD caused 7,691 deaths, with a mortality rate of 29.6 per 100,000 people, representing 4% of all deaths. Therefore, the increasing prevalence of respiratory diseases is driving the growth of the dyspnea market.

Major companies operating in the dyspnea market are focusing on developing innovative drug therapies such as phosphodiesterase (PDE) inhibitors to improve treatment efficacy, reduce respiratory symptoms, and provide better relief for patients with chronic breathing difficulties. A phosphodiesterase (PDE) inhibitor is a medication that blocks PDE enzymes, increasing intracellular cyclic AMP or cyclic GMP levels, which promotes bronchodilation, reduces inflammation, and enhances overall respiratory function. For instance, in May 2024, Verona Pharma Plc, a UK-based biopharmaceutical company, announced preparations for the anticipated U.S. launch of ensifentrine, a first-in-class dual PDE3/4 inhibitor for chronic obstructive pulmonary disease (COPD), expected in Q3 2024 pending FDA approval. Delivered via nebulization, ensifentrine demonstrated significant reductions in COPD exacerbation rates and meaningful improvements in dyspnea during Phase III trials. Verona secured $650 million in financing to support its commercial rollout and further development, including a planned Phase II fixed-dose combination trial with glycopyrrolate for maintenance COPD therapy.

In October 2025, Merck & Co. Inc., a US-based biopharmaceutical company, acquired Verona Pharma Plc for approximately $10 billion. Through this acquisition, Merck aims to strengthen and diversify its cardiopulmonary portfolio by adding a novel, first-in-class COPD treatment. Verona Pharma Plc is a UK-based biopharmaceutical company that develops treatments clinically proven to improve dyspnea.

Major companies operating in the dyspnea market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Inogen Inc, Fisher & Paykel Healthcare, ResMed Inc, Koninklijke Philips N.V, Masimo Corporation, Breas Medical, PARI Medical Holding GmbH, BMC Medical, Hamilton Medical, Nihon Kohden Corporation, Cipla Inc.

North America was the largest region in the dyspnea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyspnea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dyspnea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dyspnea market by increasing costs of imported oxygen concentrators, respiratory devices, and inhalation therapies. Hospitals and homecare providers are most affected due to reliance on imported respiratory equipment. These tariffs increase treatment costs by raising equipment acquisition and maintenance expenses, impacting access to respiratory support in chronic care settings. However, they promote regional manufacturing of respiratory care devices, strengthening local production and improving equipment availability.

The dyspnea market research report is one of a series of new reports that provides dyspnea market statistics, including dyspnea industry global market size, regional shares, competitors with a dyspnea market share, detailed dyspnea market segments, market trends and opportunities, and any further data you may need to thrive in the dyspnea industry. This dyspnea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dyspnea refers to difficulty breathing or shortness of breath. It describes the sensation of not getting enough air into the lungs, which can present as chest tightness, gasping, or increased effort to breathe. Dyspnea is assessed using various clinical methods and tools to determine its severity, impact on daily life, and underlying causes.

The main treatments for dyspnea include supplemental oxygen therapy and relaxation therapy. Supplemental oxygen therapy delivers oxygen to increase blood oxygen levels, supporting breathing in patients with respiratory conditions or those recovering from severe illnesses. Drug classes used in treatment include anti-anxiety medications, antibiotics, anticholinergic agents, corticosteroids, and others. These drugs are administered via various routes, such as oral, inhalation, and others, and are utilized by end users including hospitals, home care providers, specialty clinics, ambulatory services, and other healthcare settings.

The dyspnea market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, oxygen therapy, respiratory monitoring, telemedicine consultations, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyspnea market also includes sales of products such as bronchodilators, ventilators, nebulizers, portable oxygen concentrators, and pulmonary function testing devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The IT market is segmented into IT services, computer hardware, telecom, and software products.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.